Meeting
2023 ASCO Annual Meeting
Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.
Authors
Dorte Nielsen
Herlev, Copenhagen, Denmark
Dorte Nielsen , Erik Jakobsen , Sven Tyge Langkjer , Hella Danoe , Eva Balslev , Ann Knoop , Iben Kümler , Ida Kappel Buhl , Steen Knudsen , Anker Hansen , Mogens Winkel Madsen , Ulla Hald Buhl , Nils Meland , Knut Smerud , Peter Buhl Jensen , Ulrik Niels Lassen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
NCT01861496
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3130)
DOI
10.1200/JCO.2023.41.16_suppl.3130
Abstract #
3130
Poster Bd #
328
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor, in patients with locally advanced or metastatic breast cancer: Updated results from an on-going phase II study.
First Author: Tamta Makharadze
Poster
2022 ASCO Annual Meeting
Phase II trial of perioperative chemotherapy of esophageal cancer: PIECE trial.
First Author: Motoo Nomura
Poster
2020 ASCO Virtual Scientific Program
Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.
First Author: Hristos Z. Kaimakliotis
Poster
2020 ASCO Virtual Scientific Program
Pharmacokinetics, safety, and early activity of a nanoparticle micellar formulation of docetaxel in women with metastatic breast cancer: Results of two randomized trials (phase I and II).
First Author: Markus Joerger